DeepMed Research

Mecasermin

Generic Name: Mecasermin

Brand Names: Increlex

Drug Type: Biotech

CAS Number: 68562-41-4

Unique Ingredient Identifier: 7GR9I2683O

Background: Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

Indication: For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH . It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.

Associated Conditions: Primary Insulin-like Growth Factor-1 Deficiency

Clinical Trials

Gene Expression Changes In Young and Geriatric Skin

Early Phase 1

Recruiting

Conditions: UVB Phototherapy Burn
Insulin-like Growth Factor 1
Aging

Interventions: Other: No Insulin-Lie Growth Factor 1
Drug: Insulin-Like Growth Factor 1

First Posted Date: 2019-04-30

Last Posted Date: 2025-02-06

Lead Sponsor: Wright State University

Target Recruit Count: 24

Registration Number: NCT03932162

Locations: 🇺🇸
Wright State Physicians, Fairborn, Ohio, United States

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Phase 1

Completed

Conditions: Short Stature

Interventions: Drug: Increlex

First Posted Date: 2015-12-21

Last Posted Date: 2024-02-28

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 7

Registration Number: NCT02636270

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Phase 2

Terminated

Conditions: Autism Spectrum Disorder

Interventions: Drug: Placebo/saline
Drug: IGF-1

First Posted Date: 2013-10-28

Last Posted Date: 2024-02-08

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 3

Registration Number: NCT01970345

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: 0.9% Saline
Drug: Increlex

First Posted Date: 2012-04-30

Last Posted Date: 2012-04-30

Lead Sponsor: Peter Bang

Target Recruit Count: 8

Registration Number: NCT01588093

Locations: 🇸🇪
Pediatric Endocrinology Unit, Dept of Women's and Children's Health, Karolinska Institute & University Hospital, Stockholm, Sweden

IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients

Not Applicable

Completed

Conditions: Ehlers-Danlos Syndrome, Classic

Interventions: Drug: mecasermin
Drug: Saline

First Posted Date: 2011-10-05

Last Posted Date: 2012-11-20

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 15

Registration Number: NCT01446783

Locations: 🇩🇰
Institute of Sportsmedicine Copenhagen, Copenhagen, Denmark

Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack

Phase 1

Completed

Conditions: Heart Failure
Myocardial Infarction

Interventions: Drug: mecasermin
Drug: 0.9% sodium chloride injection

First Posted Date: 2011-09-21

Last Posted Date: 2017-03-30

Lead Sponsor: University College Cork

Target Recruit Count: 47

Registration Number: NCT01438086

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇮🇪
Cork University Hospital, Cork, Ireland

Effects of IGF-I in HIV Metabolic Disease

Phase 1

Terminated

Conditions: HIV Lipodystrophy

Interventions: Drug: mecasermin
Drug: Placebo control

First Posted Date: 2011-04-06

Last Posted Date: 2016-03-23

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 16

Registration Number: NCT01329744

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Not Applicable

Withdrawn

Conditions: Growth Failure
Chronic Liver Disease

Interventions: Drug: Increlex

First Posted Date: 2011-03-14

Last Posted Date: 2016-07-14

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT01314508

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: IGF-1

First Posted Date: 2010-09-23

Last Posted Date: 2021-01-20

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 44

Registration Number: NCT01207908

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recruiting

Conditions: IGF1 Deficiency

First Posted Date: 2009-05-15

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 500

Registration Number: NCT00903110

Locations: 🇫🇷
Pole medical Bel'Air, Mulhouse, France
🇫🇷
Centre Hospitalier de Blois, Blois, France
🇫🇷
Hôpital Jean Verdier, Bondy, France

and more 55 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy